Roche's Emicizumab Progresses Against Hemophilia's Next Big Challenge: Patients With Factor VIII Inhibitors

Interim results from the first patients enrolled in the Phase III HAVEN 2 study suggest Roche’s potential anti-hemophilia monoclonal antibody emicizumab reduces bleeds over time in younger as well as in older patients with inhibitors to factor VIII.